MRNA Stock News: Moderna set to rise on Trump's vaccine push, rivals' issues

NASDAQ: MRNA has defied markets and advanced by nearly 3% on Wednesday.
Moderna Inc. is set to extend gains as President Trump insists a vaccine will be ready shortly.
AstraZeneca's temporary vaccine halt and Pfizer's enlargement of its trial put Moderna in a pole position.

Yohay Elam FXStreet

Why is NASDAQ: MRNA moving higher? The main focus for investors has been the firm's advanced efforts to develop a COVID-19 vaccine. Moderna is busy running a final Phase 3 trial involving tens of thousands of people.

President Donald Trump has been pushing strongly for immunization to arrive in the US before the elections on November 3. He would like to paint a victorious picture, countering his mishandling of the virus so far 0 especially as America's death toll is nearing 200,000. Contrary to statements by Robert Redfield, head of the Center for Diseae Control, and Anthony Fauci, America's leading epidemiologist, he stated a vaccine is coming soon.

The president's words imply any pharmaceutical firm that announces positive results would receive emergency approval – and perhaps government funds to ramp up manufacturing.

Moderna is not alone in the race to register a full solution for the coronavirus pandemic. Pharma behemoth Pfizer is also conducting a Phase 3 trial in collaboration with Germany's BioNtech. That project asked to enlarge the number of participants from 30,000 to 44,000 without any clear explanations. Even if this move makes sense, it will likely slow Pfizer's attempt to reach a vaccine.

Another leading project comes from Britain's AstraZeneca. The project that involves the University of Oxford suffered a one-week pause after a participant fell ill. The trial later resumed, but the delay 0 and potentially others down the road – may put it behind.

All in all, Moderna is moving forward, and the mix of issues at the competition and a push from Uncle Sam put it in a pole position to win the race.

MRNA Stock Price

When a stock rises when the market falls – it is showing strength. That is what Moderna is experiencing, and for good reasons. The Massachusets-based pharma firm's stock rose by nearly $2 or 2.93% on Wednesday, closing at $48.84. It is changing hands at just above $70 in Thursday's pre-market trading.

Previously about the firm:

MRNA Stock Price: Moderna hits record high amid coronavirus vaccine progress, new test underway

Author

Yohay Elam

FXStreet

Yohay is in Forex since 2008 when he founded Forex Crunch, a blog crafted in his free time that turned into a fully-fledged currency website later sold to Finixio.

AUD/USD consolidates gains above 0.700; focus on CPI data

AUD/USD has regained composure on Tuesday, reversing the previous day’s pullback and further extending its move past the key 0.7000 yardstick. The pair’s recovery has come despite another solid day for the Greenback ahead of the FOMC gathering. Moving forward, the release of inflation figures will be the main focus in Oz on Wednesday.

USD/JPY sticks to modest gains above 157.50 as traders await Fed, BoJ meetings

USD/JPY attracts buyers for the third straight day, recovering further from a one-month low ahead of Wednesday’s FOMC decision and the BoJ policy update on Friday. Meanwhile, expectations that the BoJ may hold off on aggressive rate hikes weigh on the Japanese Yen, and the US Dollar advances to a nearly two-week high, supporting the currency pair.

Gold holds above $4,000 as traders brace for Fed interest rate decision

Gold edges higher during American trading hours on Tuesday after trading in negative territory earlier in the day. A slight decline in Oil prices offers some relief, although a firmer USD limits the upside as traders await the Fed’s monetary policy announcement on Wednesday.

Dogecoin Price Forecast: DOGE bulls eye potential bottom amid steady retail interest

Dogecoin (DOGE) trades sideways on Tuesday between the $0.0750 support and $0.0800 supply. The meme coin outlook aligns with persistent neutral-to-bearish sentiment, accentuated by macro concerns ahead of Wednesday's Federal Reserve (Fed) interest rate decision.

Experts agree: Fed policy outlook and geopolitical tensions keep US Dollar bid

The US Dollar Index rallies 0.6% in three days and hits fresh two-week highs above 102.00. Investors return to the US Dollar as markets brace for a hawkish hold by the Fed on Wednesday. Waning hopes of any immediate US-Iran peace deal have provided additional support to the safe-haven USD.

Anthropic pledged $270 billion to Amazon, Google, and Microsoft. Here's who actually gets paid

Anthropic owes Amazon, Google, and Microsoft at least $269.4 billion for computing power, even if it uses less. All three sell its models and handle its billing, and Amazon and Google own stakes and lend it money, so they get paid regardless of how the IPO goes. The Dario Amodei-led Anthropic filed its initial public offering (IPO) on Monday, seeking a listing on the Nasdaq under the ticker ANT.